AA
27
5
SCHW
40
3
ORLY
48
3
DHI
36
3
XEL
48
11
WMT
68
-2
MHK
25
5
PCG
59
9
SWK
53
4
UPS
51
6
AFL
34
6
GME
61
2
EMC
30
-26
CAH
44
7
ES
12
3
SNA
56
3
VRSK
54
2
MRK
25
2
FCX
44
4
EQT
47
13
AA
27
5
SCHW
40
3
ORLY
48
3
DHI
36
3
XEL
48
11
WMT
68
-2
MHK
25
5
PCG
59
9
SWK
53
4
UPS
51
6
AFL
34
6
GME
61
2
EMC
30
-26
CAH
44
7
ES
12
3
SNA
56
3
VRSK
54
2
MRK
25
2
FCX
44
4
EQT
47
13
Financhill
Back

Perspective Therapeutics 10K Form

Sell
23

CATX
Perspective Therapeutics

Last Price:
$2.87
Seasonality Move:
41.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.6M
Cash Flow: $-26.3M
Price / Cash Flow: 0
Annual Sales: $4.86
Price / Book: 0.59

Profitability

EPS (TTM): -1.46000
Net Income (TTM): $-63.8M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Sell
23
Perspective Therapeutics (CATX) is a Sell

Is Perspective Therapeutics a Buy or a Sell?